Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Nicolas Hoertel
Abstract
In a large, multicenter, retrospective cohort study of 83 584 patients with laboratory-confirmed COVID-19 who had an emergency department or urgent care visit or were admitted for observation or hospitalized across 87 health care centers in the US, Oskotsky et al 1 observed an association between selective serotonin reuptake inhibitor (SSRI) administration and reduced mortality in 3401 patients with COVID-19 compared with 6802 matched control patients who were not given SSRIs but shared similar sociodemographic characteristics, medical comorbidities, and medication indication.
Topics & Concepts
FluvoxamineFluoxetineSerotonin reuptake inhibitorReuptake inhibitorCoronavirus disease 2019 (COVID-19)Serotonin Uptake InhibitorsAntidepressantSerotoninPsychiatryPsychologyMedicinePharmacologyInternal medicineDiseaseAnxietyInfectious disease (medical specialty)ReceptorPharmacological Receptor Mechanisms and EffectsTryptophan and brain disordersLong-Term Effects of COVID-19